The top 3 holdings of LABU are Alnylam Pharmaceuticals (ALNY) (2.444%), Halozyme Therapeutics (HALO) (1.934%) and Incyte (INCY) (1.905%).

FUND	HOLDING	% OF FUND	VALUE ($)
LABU	Alnylam Pharmaceuticals (ALNY)	2.444%	$15.8M
LABU	Halozyme Therapeutics (HALO)	1.934%	$12.5M
LABU	Incyte (INCY)	1.905%	$12.3M
LABU	Insmed (INSM)	1.871%	$12.1M
LABU	United Therapeutics (UTHR)	1.816%	$11.7M
LABU	Regeneron Pharmaceuticals (REGN)	1.812%	$11.7M
LABU	Biomarin Pharmaceutical (BMRN)	1.745%	$11.3M
LABU	AbbVie (ABBV)	1.742%	$11.2M
LABU	Neurocrine Biosciences (NBIX)	1.696%	$10.9M
LABU	Gilead Sciences (GILD)	1.692%	$10.9M
LABU	Amgen (AMGN)	1.636%	$10.6M
LABU	Biogen (BIIB)	1.61%	$10.4M
LABU	Moderna (MRNA)	1.608%	$10.4M
LABU	BridgeBio Pharma (BBIO)	1.578%	$10.2M
LABU	Exelixis (EXEL)	1.514%	$9.8M
LABU	Madrigal Pharmaceuticals (MDGL)	1.465%	$9.5M
LABU	Natera (NTRA)	1.419%	$9.2M
LABU	Vertex Pharmaceuticals (VRTX)	1.392%	$9M
LABU	EXACT Sciences (EXAS)	1.3%	$8.4M
LABU	Roivant Sciences (ROIV)	1.191%	$7.7M
LABU	Crispr Therapeutics (CRSP)	1.116%	$7.2M
LABU	Avidity Biosciences (RNA)	1.052%	$6.8M
LABU	Cytokinetics (CYTK)	1.042%	$6.7M
LABU	Ionis Pharmaceuticals (IONS)	1.037%	$6.7M
LABU	Viking Therapeutics (VKTX)	0.977%	$6.3M

Holdings are tracked for approximately 2000 ETFs.